Elevated levels of wild-type R-RAS2 are present in various cancers, including esophageal tumors [21], oral cancer [22], skin cancer [23], lymphoma [24], and chronic lymphocytic leukemia (CLL) in which R-RAS2, in addition to its role in cancer, also regulates immunological development and homeostasis, mainly via the PI3K signaling pathway [20]. This evidence concerns the gene RRAS2 and B-cell chronic lymphocytic leukemia.